BioHaven pronounces report date for anticipated spin-off

New Haven, Conn., September 18, 2022 /PRNewswire/ — Biohaven Pharmaceutical Holding Co., Ltd. (NYSE: BHVN) (“Biohaven”) at present introduced that it has set a report date. September 26, 2022 (“report date”) for a beforehand introduced spin-off by Biohaven of its Biohaven Restricted (“Spinco”) subsidiary, which can personal the Kv7 ion channel activators, glutamate modulation, myeloperoxidase … Read more

BioHaven declares document date for anticipated spin-off

New Haven, Conn., September 18, 2022 /PRNewswire/ — BioHaven Pharmaceutical Holding Firm Restricted (NYSE: BHVN) (“BioHaven”) at present introduced that it has set a document date for the beforehand introduced spin-off as September 26, 2022 (“Report Date”) . Biohaven, a subsidiary of Biohaven Restricted (“Spinco”), which can personal KV7 ion channel activators, glutamate modulation, myeloperoxidase … Read more